The Synthesis and In Silico Antihypertensive Activity Prognosis of New Mannich Bases Containing the 1,2,4-Triazole Moiety

2020;
: pp. 214 - 220
1
National University of Pharmacy
2
National University of Pharmacy
3
National University of Pharmacy
4
Danylo Halytsky Lviv National Medical University
5
Lviv Polytechnic National University
6
National University of Pharmacy
7
National University of Pharmacy
8
National University of Pharmacy
9
Institute of Pharmacology and Toxicology, National Academy of Medical Sciences; Nizhyn Mykola Gogol State University

As a part of our continuous research on potential antihypertensive agents among morpholine and piperidine derivatives, 10 novel target compounds containing 1,2,4-triazole and morpholine or piperidine moieties have been designed and synthesized, and the docking studies have been conducted in order to find biologically active substances with the antihypertensive activity. The in silico studies have shown that all compounds synthesized are promising angiotensin converting enzyme inhibitors and belong to the toxicity class 4 and 5 according to the classification of chemicals by the OECD project.

  1. Kang D., Fang Z., Huang B. et al.: Chem. Biol. Drug Design, 2015, 86, 568. https://doi.org/10.1111/cbdd.12520
  2. Drapak І., Zimenkovsky B., Perekhoda L. et al.: Pharmacia, 2019, 66, 33. https://doi.org/10.3897/pharmacia.66.e35083
  3. Ueda Y., Timothy P., Wang I. et al.: Pat. US 8461333 B2, Publ. Jun. 11, 2013.
  4. Yradjan M., Yradjan N., Paronykjan R., Stepanjan H.: Khimiko-Farmacevt. Zh., 2010, 44, 11.
  5. Klen E., Makarova N., Chalyullyn F. et al.: Bashkirsky Khim. Zh., 2008, 15, 112.
  6. Jakhmola V., Jawla S., Mishra R.: Acta Sci. Pharm. Sci., 2018, 2, 02.
  7. Al-Ghorbani M., Begum B. et al.: J. Chem. Pharm. Res., 2015, 8, 611. https://doi.org/10.5958/0974-360X.2015.00100.6
  8. Kourounakis A., Xanthopoulos D., Tzara A.: Med. Res. Rev., 2020, 40, 709. https://doi.org/10.1002/med.21634
  9. Yan X., Wang Z., Qi P. et al.: Eur. J. Med. Chem., 2019, 177, 425. https://doi.org/10.1016/j.ejmech.2019.05.056
  10. Ladopoulou E., Matralis A., Nikitakis A., Kourounakis A.: Bioorg. Med. Chem., 2015, 23, 7015. https://doi.org/10.1016/j.bmc.2015.09.034
  11. Mytnyk Z., Kolesnyk Ju.: Zaporozhsky Med. Zh., 2010, 12, 79.
  12. Bhat M., Al-Omar M., Ghabbour H., Naglah A.: Molecules, 2018, 23, 1559. https://doi.org/10.3390/molecules23071559
  13. Manjusha R., Begum S., Begum A., Bharathi K.: Asian J. Pharm. Clinical Res., 2018, 11, 66. https://doi.org/10.3390/molecules23071559
  14. Kaplaushenko A.: Naukovyi Zh. MOZ Ukrainy, 2013, 3, 152.
  15. Sahu N., Sahu J., Kaushik A.: Curr. Res. Pharm. Sci., 2013, 3, 108.
  16. Malani A., Makwana A., Makwana H.: Moroccan J. Chem., 2017, 5, 41.
  17. Liu J., Liu Q., Yang X. et al.: Bioorgan. Med. Chem., 2013, 21, 7742. https://doi.org/10.1016/j.bmc.2013.10.017
  18. Zhou C.-H., Wang Y.: Current Medicinal Chemistry, 2012, 19, 239. https://doi.org/10.2174/092986712803414213
  19. http://accelrys.com/
  20. http://www.way2drug.com/gusar/acutoxpredict.html
  21. Drapak I., Suleiman M., Protopopov M. et al.: Res. J. Pharm. Technol., 2019, 12, 4889. https://doi.org/10.5958/0974-360X.2019.00846.1
  22. Anthony C., Corradi H., Schwager S. et al.: J. Biol. Chem., 2010, 285, 35685. https://doi.org/10.1074/jbc.M110.167866
  23. Kramer G., Mohd A., Schwager S. et al.: ACS Med. Chem. Lett., 2014, 5, 346. https://doi.org/10.1021/ml4004588
  24. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpa...